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Summary Biopsies from 26 patients with advanced stage squamous cell carcinoma of the head and neck were
investigated to determine the intensity of the inflammatory cellular infiltrate and the expression of leucocyte
antigens. Mononuclear cell infiltration varied considerably between the individual patients and also within the
tumour. Tumour-infiltrating cells consisted mainly of T lymphocytes and monocytes (Mo)/macrophages (MO).
Staining procedure with monoclonal antibodies (moabs) against Mo/MO revealed different clusters of antigen
expression: (1) moabs 27E10 and a-CD35 detected a subgroup of Mo/MO with particular staining of perivasal
Mo; (2) moab a-CDI stained preferentially cells in tumour cell clusters; (3) moabs that reacted with cells of
either typical MO or dendritic morphology throughout the tumour-tissue: a-Fc'y receptor I-III, a-class II
antigens, a-CD4, Rm3/1, a-CD36 and 25F9. Thus, the majority of tumour-infiltrating mononuclear phagocytes
were found to possess a rather mature phenotype. The number of Mo/MO with mature phenotype within the
tumours correlated with T lymphocyte infiltration in the tissue.
Tumour growth is influenced by cells and/or products of the
tumour's microenvironment. These influences are mainly due
to cells of the defence system (Boheim et al., 1987; Kopper &
Lapis, 1985; Zeromski et al., 1986; Kabawat et al., 1983). In
vitro assays have demonstrated a significant role for T cells,
natural killer (NK) and lymphokine-activated killer (LAK)
cells in killing and lysing of neoplastic cells (Patek & Collins,
1988; Strohme et al., 1987; Whiteside et al., 1988; Vinzenz &
Micksche, 1987; Gottlinger et al., 1985). Activated macro-
phages (Me), also, can bind to and destroy neoplastic cells in
vitro and in vivo (Fidler & Schroit, 1984; Fidler & Schroit,
1988; Kopper & Lapis, 1985). Furthermore, MO, via cyto-
kines, are capable of enhancing lymphocyte-mediated
immunity (Bentzen, 1988). On the other hand, depending on
their localisation in tissue, MO may enhance rather than
inhibit tumour growth, possible by triggering local immuno-
suppression (Gronberg et al., 1989; Kopper & Lapis, 1985;
Yamanaka et al., 1988; Kronke, 1988). Considering this
bimodal role of MS in immunesurveillance of tumours in
vitro we focused our studies on the phenotype and surface
receptor expression of MO, which could be involved in local
immunesurveillance of malignant growths.
Patients and methods
Patients
The study group consisted of 28 patients with histologically
confirmed diagnosis of a squamous cell carcinoma of the
upper gastro-intestinal and respiratory tract with varying
degree of differentiation (Table I). All patients were in an
advanced stage of their disease, graded T3 and T4 according
to the UICC classification of 1987 (Hermanek et al., 1987);
14 patients had evidence of regional metastases, none had
distant metastases at the time of surgery. The patients' (25
males, three females) ages ranged from 35 to 71 years
(median 56.5). The patients had not received chemotherapy,
radiotherapy or previous surgery.
Preparation oftissue sections
Excised tissue blocks, consisting macroscopically of tumour
taken from the primary tumour focus, were snap-frozen in
liquid-nitrogen cooled methylbutan and stored under liquid
nitrogen until use. Serial cryostat sections (61nm), mounted
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on glass slides were air-dried for 2 h and fixed at room
temperature for 5 min in acetone, then for 5 min in chloro-
form and finally for 5 min in acetone. The rest of the tumour
was fixed in 40% formaldehyde and embedded in paraffin;
sections were stained with haematoxilin-eosin for diagnosis
and grading at the Department of Pathology of the Univer-
sity of Vienna.
Immunocytochemistry
Source and specificity of monoclonal antibodies (moabs) are
listed in Table II. Appropriate dilutions were determined in
preliminary experiments. Immunostaining was performed
with an indirect peroxidase system as described in detail
earlier (Koller et al., 1986).
Double immunostaining
To distinguish between CD4+ MO and other CD4+ cells or
between CD16+ granulocytes and other CD16+ cells, a doub-
le immunohistochemical staining was employed. First, moabs
Table I Patient details
Patient TU localisation TNM TU histological grading
I oropharynx T3N3 high
2 T4N2 high
3 T4N3 high
4 T4N2 poor
5 T4No high
6 T3No poor
7 T3No high
8 hypopharynx T4N3 high
9 T4N3 moderate
10 T4N2 poor
11 T4N2 high
12 T3No high
13 T3N3 high
14 T4No high
15 T4No moderate
16 T4N2 poor
17 T4N2 poor-moderate
18 T4N, moderate-high
19 T4N3 poor
20 T3No poor
21 larynx T4No high
22 T4No high
23 T3N3 moderate
24 T4N2 moderate
25 T4N2 high
26 T4No moderate
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Table II Monoclonal antibodies
Dilution Specificity
1:50 all T cells, CD3
1:3 T helper/inducer, CD4
1:50 T cytotoxic/suppressor, CD8
1:3 B cells, CD 22
1:1000 granulocytes, CD15
1:100 B cells, Mo/MO
1:100 B cells, Mo/MO
1:100 B cells, Mo/M4
1:100 Mo/M0, granulocytes activated
T cells, CDI b (CR3)
1:200 dendritic reticulum cells, B cells,
subset of Mo/MO, red cells,
granulocytes, CD35
1:1000 FcyR I, CD64
1:1000 Fc'yR II, Mo/M4, granulocytes, B
cells, endothelium, CD32
1:100 FcyRIII, granulocytes, NK cells,
CD16
1:100 60-90% thymocytes, Langerhans
cells in the skin, CD1
1:25 Subpopulation of Mo/MED,
granulocytes
1:50 Mo, thrombocytes, CD36
Source
BD (Ledbetter et al., 1981)
BD (Wood et al., 1983)
BD (Evans et al., 1981)
BD (Leukocyte typing II)
(Gooi et al., 1983)
BD (Lampson & Levy, 1980)
BD (Chen et al., 1984)
BD (Chen et al., 1984)
(Knapp et al., 1984)
Dako (Gerdes et al., 1982)
Medarex (Graziano & Fanger, 1987)
Medarex (Looney et al., 1986)
Behring (Simmons & Seed, 1988)
BD (Wood et al., 1983
(Zwadlo et al., 1986)
Ortho
(Zwadlo et al., 1985)
(Zwadlo et al., 1987)
Leu4 (a-CD3) or VEP9 (a-CD15) were used as described
before and staining procedure continued with the respective
second moab (Leu3a=a-CD4 or BW209=a-CD16) using
an alkaline phosphatase/anti-alkaline phosphatase technique
(Cordell et al., 1984). Controls consisted of irrelevant anti-
bodies of the IgGI (BIP-1) and IgM (SQ4F3) isotypes respec-
tively. Both control moabs reacted with Bet v I, the major
allergen from birch pollen (Jarolim et al., 1989).
Evaluation oftumour infiltrating cells
Cells were counted in five representative areas in a square
lattice with 100 squares sized 0.04 x 0.04 mm; final
magnification x 400. Positive cells were expressed as absolute
numbers of immunostained cells per mm2. Statistical correla-
tion was performed by linear regression analysis and as the
values were unevenly distributed, a non parametric test was
used (Mann-Whitney U test) as a two group test.
Results
Clinical histopathology
The tumours were graded histologically into 15 cases of
highly, five cases of moderately and eight cases of poorly
differentiated squamous cell carcinomas. Mononuclear cell
infiltration of the tumours was found to vary considerably
between the individual patients and also within each tumour.
T cells, defined by a-CD3, a-CD4 and a-CD8 moabs and
MO, stained by MOb-markers (Table II) were located pre-
dominantly in the tumour stroma. Variable numbers of T
cells (58-1017 mm-2) and particularly MO (197-1397 mm-2)
were found, some of which had infiltrated also into the
tumour cell clusters. Quantitation of tumour-infiltrating cells
in 22 patients revealed marked T cell infiltration and con-
comitantly high numbers of MO (Figure 1).
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Figure 1 Leucocyte surface antigen-expression on tumour-infiltrating cells: Columns show median values: high T cell infiltration
and strong expression of HLA-DR, HLA-DP, FcyRI (CD64), II (CD32), III (CD16), CD4 and Rm3/1 in 22 patients. In contrast,
significant fewer MO of patients with low T cell infiltration expressed MO-antigens characteristic for mature and activated MO.
Antibody
Anti Leu4
Anti Leu3a + b
Anti Leu2a
Anti Leu14
VEP 9
Anti HLA-DR
Anti HLA-DQ
Anti HLA-DP
Vim-12
Anti-CRI
3-2
4-3
BW209
Anti Leu6
27E10
OKM5
25F9
RM3/1
Subclass
IgGI
IgGI
IgGI
IgG2b
IgM
IgG2a
IgGI
IgGI
IgGI
IgGI
IgGI
IgG2b
IgGI
IgG2b
IgGI
IgGI
IgGI
IgGI
1:25
1:100
mature MO
mature MS
**** P< 0.001
** P<0.01750 C. NEUCHRIST et al.
Markerfor Mo/MO subpopulations
Staining by moabs directed against the three FCTy receptors
(Figure 2f,g,h), CD4 (Figure 2c), HLA-DR (Figure 4a),
HLA-DP and the Rm3/1 (Figure 2e) antigens respectively,
was found on most MO present in the specimen studied
(500-1400 cellsmm-2). Antibodies of this cluster also cor-
related significantly with each other (Table III). The number
of MO expressing complement receptors CR1 (CD35) and
CR3 (CDllb) varied considerably, forming thus an inter-
mediate group with respect to antigen expression. Moabs
a-CDI, a-CD36, a-HLA-DQ, 25F9 and 27E10 recognised
only subgroups of Mo/MO and were found on about
25-40% of MO, defined by HLA-DR and a-Fcy receptor
I-III moabs (Figure 3). Out of these moabs, only a-CD1lb
correlated significantly with the cluster of moabs mentioned
above (Table III). The other moabs (a-CD1, a-CD35, a-
CD36, a-HLA-DQ, 25F9, 27E10) formed a different group
showing strong correlation between CD36 and CD35
(r = 0.772 P<0.001). Moabs 27E10 and a-CD36 particularly
stained perivascular cells with monocyte morphology (Figure
3b,d). Anti-CD1, which recognises an epitope on Langerhans
cells of the skin, in most cases stained only few cells in
tumour specimens, which - unlike T cells or other MO -
were found mainly within solid tumour nests (Figure 3a).
In six patients, only small numbers (58-155 mm-2) of
CD3+ lymphocytes were present in the tumour tissue, and in
these cases also the number of MO was low (169-
502 mm-2). The differences in the MO-marker expression
between these six and the other 22 patients were significant
with respect to moabs a-CD4, a-Fc'y receptors I, II, III,
a-HLA-DR and Rm3/1. Only minor or no significant
differences were seen with the other Mo/Mb moabs 27E10,
a-CD1, 25F9, a-CD36, a-CD35, a-HLA-DQ and a-CD1lb
(Figure 1).
Figure 2 Immunostaining on cryostat sections of tumour tissue with monoclonal markers directed against leucocyte surface
antigens. a-h, x 244.4, interference contrast, counterstained with nuclear fast red. a, Section stained with a-CD3 (T lymphocytes).
b, Adjacent section stained with a-CD8. c, Area similar to that in a and b stained with a-CD4. d, Cells stained with a-CDllb
(CR3). e, Cells stained with moab Rm3/1. Cells stained with a-CD64 (FcyRI, f), a-CD32 (FcyRII, g) and a-CD16 (FcyRIII, h).
Note the dendritic morphology found of positive cells in c-h (bin).SQUAMOUS CELL CARCINOMA 751
Table In Correlations of antigen expression
moabs CD4-MI CD64 CD32 CD16 CD3
CD4-M4) 1 0.584** 0.640** 0.793*** 0.718***
CD64 0.584** 1 0.696*** 0.696*** 0.507*
CD32 0.640** 0.883*** 1 0.803*** 0.414*
CD16 0.793*** 0.696*** 0.803*** 1 0.538**
CD3 0.718*** 0.507* 0.414* 0.538** 1
HLA-DR 0.438* 0.518* 0.520* 0.511** 0.383*
HLA-DP 0.383* 0.534* 0.615** 0.591** 0.437*
Rm3/1 0.202ns 0.771*** 0.665*** 0.479* 0.113ns
CDI 0.576** 0.286ns 0.452* 0.602** 0.185ns
25F9 0.346ns 0.244n.s 0.158ns 0.404* 0.070ns
CDI lb 0.310 nlS 0.228ns 0.292ns 0.468* 0.303ns
***P<0.001; ** P<0.01; *P<0.05. n.s. = not significant.
6 ,
Figure 3 Distribution of Mo/M4 markers in tumour tissue. a-e, Cryostat sections, x 249.6, interference contrast, counterstained
with nuclear fast red. a, Cells stained with a-CDI (Langerhans cells of the skin). Positive cells are found rather in the solid tumour
than in the stroma. b, Section stained with moab 27E10 (subpopulation monocytes). Only few cells with monocyte-like appearance
are labelled. c, Similarly, only few cells are detected by a-CD35 (CRI), similar in shape to that seen in b. d, Cells stained with
a-CD36 (Mo/MO). Note the perivascular position of positive cells as found in b (j). e, 25F9+cells (mature M0).
Figure 4 Expression of Mo/M0 markers on tumour cells. a-c, x 234, interference contrast, counterstained with nuclear fast red.
a, Cells with MO-morphology (-) but also tumour cells (+) stain positive with a-HLA-DR. b, Tumour cells show reactivity with
27E10 (Mo). c, Tumour cells, forming a horny pearl, stain positively for a-CD36 (Mo/MO) (+). In the upper left corner a CD36+
MO
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Independently from the histological grading of the whole
tumour, in 11 cases the tumour cells expressed class II
antigens (Figure 4a). In 13 specimens, tumour cells forming
more differentiated parts - like horny pearls or stratified
epithelium - reacted with moab 27E10 and a-CD36 (Figure
4b,c).
Low numbers of B cells (CD22+ cells) and granulocytes
(CD15+ cells) were detected in the tissues studied, the latter
cells being found predominantly in necrotic areas (data not
shown).
Discussion
The highly divergent results on the numbers of tumour infil-
trating Mo/Mb may be due to the fact that these cells mainly
express functional antigens, present on the surface of these
cells only during certain steps of activation. Characterisation
ofcultured blood Mo showed that at the beginning ofculture
about 60% express the 27E10-antigen (Zwadlo et al., 1986)
and will loose it in favour of the antigens Rm3/1 and later
25F9 (Zwadlo et al., 1985; 1987). Other studies pointed out
that cultured blood Mo gained or showed enhanced expres-
sion of Fcy-receptors (Baumgartner et al., 1988; Clarkson &
Ory, 1988), HLA-DR (Peters et al., 1987) or the CD4 antigen
(Crowe et al., 1987). The results of our study indicate that
most MS found in tumour tissues are of a functionally
'mature' phenotype. It is not surprising that in our study the
number of MO expressing these antigens correlated with a
high number of infiltrating T cells, as T lymphocyte products
may account for migration of mononuclear phagocytes and
further enhance their differentiation towards mature effector
cells (Burchett et al., 1988; Makovsky et al., 1988).
It is certainly of interest to compare the tumour infiltrate
seen in squamous cell carcinomas with the infiltrate found in
tumours and inflammatory tissues of other origin. Other
authors found that in malignant melanomas and gastric car-
cinomas 27E1O0 and 25F9+ macrophages were associated
with tumour progression (Brocker et al., 1987; Heidl et al.,
1987; Brocker et al., 1988). In acute gingival inflammation
the dominant Mo/MO population carried the 27E10 antigen,
whereas the numbers of Rm3/1 and 25F9 positive cells were
low (Zwadlo et al., 1985, 1986, 1987). Furthermore, double
staining revealed that all three markers labelled distinct, non
overlapping MO subpopulations. In contrast, in chronic
inflammatory processes high numbers of Rm3/1 and 25F9
positive cells were found, some of these cells carrying both
antigens simultaneously (Zwadlo et al., 1987). Our present
results with the tumour tissue thus resembles the pattern of
Mo/Mb infiltration found in chronic inflammatory lesions.
In spite of the marked inflammatory reaction within the
tumours of most patients, we could not correlate the number
of T lymphocytes with histological grading or tumour
differentiation. This finding makes a major influence of
tumour malignancy on the number and composition of
inflammatory infiltrates unlikely, although subtle differences
may have escaped detection because of the limited number of
patients and tumour samples investigated. Furthermore,
functional defects of immunocompetent cells or the lack of
specific immunological responses against putative tumour
antigens may explain the ineffectivity of the infiltration to
destroy the tumour tissue.
Thus, functional properties of tumour infiltrating cells have
to be characterised in vitro and in situ in more detail, by
excluding a crucial defect in cytokine and cytotoxin produc-
tion. This appears to be especially important, since trials are
already performed using immune response modifiers or spe-
cific anti-tumour antibodies in the treatment of malignancies
(Ozawa et al., 1989; Mace et al., 1988). The finding that
squamous cell carcinoma cells may express MO markers (as
MHC class II antigens, 27E10, CD36 in this study) was also
described by Russel et al. (1988), who found the expression
of PGP-1, which is strongly expressed by mouse phagocytes,
also on human bladder carcinoma cells when these cells were
transplanted into nude mice. These data suggest that these
MO antigens could be induced by mediators of the defence
system to generate additional molecules for intercellular ad-
hesion. It seems further likely that squamous carcinoma cells
only with a certain differention-grade would be able to exp-
ress these antigens.
In our study, it is shown that the tumour-infiltrating Mo/
MO population is equipped with surface antigens necessary
for enhanced cellular interaction and tumour cell killing.
These MO could eventually act as specific effector cells, e.g.
when a monoclonal antibody is added - which in turn gives
them an important role in future immunotherapy.
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